Rubicon Genomics Enters into Collaboration Agreement with OncoMethylome Sciences

ANN ARBOR, Mich., Jan. 22 /PRNewswire/ -- Rubicon Genomics, Inc. today
announced a Collaboration Agreement with OncoMethylome Sciences for the
identification of biomarkers for early detection of cancer. Rubicon plans to
use its MethylPlex(TM) platform to carry out the marker identification
analysis. As part of the agreement, Rubicon granted an option to
OncoMethylome for licensing markers resulting from the collaboration. This is
the second such marker identification agreement between the two companies, and
OncoMethylome Sciences has already licensed a set of markers from Rubicon.
Cancer cells alter the normal patterns of DNA methylation giving the tumor
the ability to grow and spread. The patterns of abnormal methylation in DNA
are strong predictors of the presence of cancer as well as other diseases.
MethylPlex(TM) is a method for identifying multi-gene patterns of abnormal DNA
methylation during tumor formation and progression.
"We believe that detection of methylated DNA biomarkers is the most
sensitive and specific method for early detection and characterization of
cancer," said Fred Beyerlein, President and CEO of Rubicon Genomics. "We are
looking forward to again be working with OncoMethylome Sciences, a recognized
leader in the field of methylation."
About Rubicon Genomics, Inc.
Rubicon, located in Ann Arbor, MI, develops and commercializes proprietary
MethylPlex(TM) based tests for non-invasive diagnosis of cancer and other
diseases, as well as kits and services to facilitate gene-based research and
drug development. For more information please contact John Langmore, VP
Commercial Development, at langmore@rubicongenomics.com or (734) 368-1705
SOURCE Rubicon Genomics, Inc.

John Langmore, VP Commercial Development of Rubicon Genomics, Inc.
+1-734-368-1705, langmore@rubicongenomics.com